Vyvanse and Nephritis - interstitial - a phase IV clinical study of FDA data

Summary:

Nephritis - interstitial is reported as a side effect among people who take Vyvanse (lisdexamfetamine dimesylate), especially for people who are male, 50-59 old, also take Promethazine, and have Gastroesophageal reflux disease.

The phase IV clinical study analyzes which people have Nephritis - interstitial when taking Vyvanse. It is created by eHealthMe based on reports of 28,083 people who have side effects when taking Vyvanse from the FDA, and is updated regularly.

What is Vyvanse?

Vyvanse has active ingredients of lisdexamfetamine dimesylate. It is often used in attention deficit hyperactivity disorder. eHealthMe is studying from 35,872 Vyvanse users. Check the latest studies of Vyvanse.

What is Nephritis - interstitial?

Nephritis - interstitial (a kidney condition characterized by swelling in between the kidney tubules) is found to be associated with 1,445 drugs and 1,570 conditions by eHealthMe. Check the latest studies of Nephritis - interstitial.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

28,083 people reported to have side effects when taking Vyvanse.
Among them, 12 people (0.04%) have Nephritis - interstitial.

Could Vyvanse cause Nephritis - interstitial?

Among these 12 people:

What is the gender of people who have Nephritis - interstitial when taking Vyvanse? *

female: 50 %
male: 50 %

What is the age of people who have Nephritis - interstitial when taking Vyvanse? *

What are other drugs people take besides Vyvanse? *

What are other side effects people have besides Nephritis - interstitial? *

Chronic Kidney Disease: 11 people, 91.67%
Acute Kidney Failure: 7 people, 58.33%
Renal Injury (kidney injury): 5 people, 41.67%
Indigestion: 3 people, 25.00%
Renal Impairment (severely reduced kidney function): 3 people, 25.00%
White Blood Cell Count Decreased: 1 person, 8.33%
Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 1 person, 8.33%
Haemoglobin Decreased: 1 person, 8.33%
Haematocrit Decreased: 1 person, 8.33%
Gamma-Glutamyltransferase Increased: 1 person, 8.33%

What are the existing conditions these people have? *

Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 10 people, 83.33%
Pain: 7 people, 58.33%
Prostate Infection: 5 people, 41.67%
Nausea (feeling of having an urge to vomit): 5 people, 41.67%
Multiple Allergies (allergy to multiple agents): 5 people, 41.67%
Infection: 5 people, 41.67%
Hypersensitivity: 5 people, 41.67%
Headache (pain in head): 3 people, 25.00%
Neuralgia (pain in one or more nerves): 2 people, 16.67%
Vasodilatation (widening of blood vessels resulting from relaxation of smooth muscle cells within the vessel walls): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Vyvanse and have Nephritis - interstitial?

- Check whether Nephritis - interstitial is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Vyvanse:

Vyvanse (35,872 reports)

Browse all side effects of Vyvanse:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nephritis - interstitial:

Nephritis - interstitial (1,445 drugs)

Browse all the conditions that are associated with Nephritis - interstitial:

Nephritis - interstitial (1,570 conditions)

Related publications that referenced our studies

Najib J, Wimer D, Zeng J, Lam KW, Romanyak N, Paige Morgan E, Thadavila A, "Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder", Journal of central nervous system disease, 2017 Aug .
Maneeton N, Maneeton B, Suttajit S, Reungyos J, Srisurapanont M, Martin SD, "Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD", Drug design, development and therapy, 2017 Jan .
Maneeton B, Maneeton N, Likhitsathian S, Suttajit S, Narkpongphun A, Srisurapanont M, Woottiluk P, "Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials", Drug design, development and therapy, 2013 Jan .
Najib J, Wimer D, Zeng J, Lam KW, Romanyak N, Paige Morgan E, Thadavila A, "Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder", Journal of central nervous system disease, 2017 Aug .
Maneeton N, Maneeton B, Suttajit S, Reungyos J, Srisurapanont M, Martin SD, "Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD", Drug design, development and therapy, 2017 Jan .
Maneeton B, Maneeton N, Likhitsathian S, Suttajit S, Narkpongphun A, Srisurapanont M, Woottiluk P, "Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials", Drug design, development and therapy, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on lisdexamfetamine dimesylate (the active ingredients of Vyvanse) and Vyvanse (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.